The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
- Author(s)
- Fjermeros, K; Ghannoum, S; Geisler, SB; Bhargava, S; Tahiri, A; Klajic, J; Lüders, T; Fongård, M; Nawaz, MS; Bosnjak-Olsen, T; Buvarp, UE; Johanna Rosenskiold, AK; Nguyen, NT; Sletbak, TT; Seyedzadeh, M; Selsås, K; Porojnicu, AC; Skjerven, HK; Hovda, T; Sahlberg, KK; Torland, LA; Lyngra, M; Hammarström, CL; Hönigsperger, EB; Noone, JC; Mathiassen, S; Hurtado, A; Goel, S; Koff, A; Tekpli, X; Kristensen, VN; Geisler, J;
- Journal Title
- Future Oncology
- Publication Type
- Online publication before print
- Abstract
- Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.Trial registration number: NCT05163106 (ClinicalTrials.gov).; [Box: see text].; eng
- Keywords
- HR positive; gut microbiome; letrozole; locally advanced breast cancer; neoadjuvant; ribociclib; senescence; single-cell RNA sequencing
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1080/14796694.2024.2377531
- Open Access at Publisher's Site
https://doi.org/10.1080/14796694.2024.2377531- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-29 04:13:42
Last Modified: 2024-08-29 04:22:13